Getting Medicines to Patients Faster with POD-Based Mini-Factories

Nov 06, 2015
November 2, 2015 – A partnership of pharmaceutical manufacturers and suppliers, including Pfizer, GEA and G-CON Manufacturing, welcomes GSK to a consortium dedicated to the development of a continuous technology solution for on-demand tablet production.

GEA, a leader in continuous manufacturing technologies, has announced a next-generation collaboration with GlaxoSmithKline (GSK) to further develop self-contained, POD-based mini-factories to develop and manufacture pharmaceutical oral solid dosage (OSD) forms. This partnership expands on GEA’s existing alliance with Pfizer and G-CON Manufacturing to design a portable, continuous, miniature and modular (PCMM) prototype unit, which is currently being implemented at Pfizer’s labs in Groton (Connecticut, USA).  

Conceived in conjunction with Pfizer and G-CON, the three companies formed a consortium to design and build an autonomous manufacturing environment for continuous OSD production using GEA’s ConsiGma™ 25 equipment and G-CON’s modular POD system.  

Recently presented with the award for Best Technologies Innovation during INTERPHEX 2015, this first-of-a-kind manufacturing system accelerates the speed at which tablets are produced. By miniaturizing the equipment, the continuous process can be enclosed in a portable, modular facility, which can be shipped by truck to any location in the world and quickly assembled. Once up and running, the system will deliver the capability to transform powders into uncoated tablets in minutes, which can take days or weeks with current technology.  

H. McCoy Knight, Vice President, APC Pharma, commented: “GEA is delighted to welcome GSK to the consortium. The involvement of another significant player from the global pharmaceutical manufacturing environment increasingly demonstrates the industry’s commitment to continuous processing and the acknowledgement that PCMM truly represents the future of on-demand drug production. We look forward to working with GSK and pushing the boundaries of our autonomous manufacturing environment for continuous OSD production even further.”  

Highlights of PCMM’s potential for smaller, more flexible, continuous processing technologies include a 60–70% smaller footprint than a conventional production facility, the ability to use the same equipment for development, clinical trials and commercial manufacturing, and significantly reduced timelines: a PCMM facility takes about one year to set up and start running compared with 2–3 years for standard processes.  

With PCMM, the consortium of partners is leading the way toward smaller, more flexible, continuous processing technologies with the potential to transform the future of pharmaceutical development and manufacturing, and deliver customized quantities of drugs to patients in need in a quick and efficient way. To discover more about these innovative, flexible and self-contained manufacturing spaces, watch the online video here or contact pharma@gea.com.

 

About GEA

GEA is one of the largest suppliers for the food processing industry and a wide range of process industries that generated consolidated sales of approximately EUR 4.5 billion in 2014. As an international technology group, the Company focuses on process technology and components for sophisticated production processes in various end-user markets. The Group generates more than 70 percent of its revenue in the sustainably growing food industry. As of June 30, 2015, the Group employed about 18,000 people worldwide. GEA is a market and technology leader in its business areas. The Company is listed in Germany’s MDAX stock index (G1A, WKN 660 200). In addition, GEA’s share is a constituent of one of the MSCI Global Sustainability Indexes. Further information is available on the Internet at www.gea.com.

If you do not want to receive any further information from GEA, please send an email to pr@gea.com

PCMM_at-Pfizer-web (2)

Photo: GEA ConsiGma™ 25 installation at Pfizer labs in Groton (Connecticut, USA).

 

Business contact:

H. McCoy Knight
Vice President, APC Pharma
Phone +1 410 997 6608
Mobile +1 410 707 1186
mccoy.knight@gea.com

 

Editorial enquiries

Marc Pönitz
Corporate Media and Press
Peter-Müller-Str. 12, 40468 Düsseldorf
Germany
Phone +49 211 9136 1500
marc.poenitz@gea.com 

www.gea.com

In case of publication, please submit two copies of each of the published items to us for our archives.